Diagnosis and prognostic markers of HCMV infection

Citation
L. Grangeot-keros et D. Cointe, Diagnosis and prognostic markers of HCMV infection, J CLIN VIRO, 21(3), 2001, pp. 213-221
Citations number
43
Categorie Soggetti
Clinical Immunolgy & Infectious Disease
Journal title
JOURNAL OF CLINICAL VIROLOGY
ISSN journal
13866532 → ACNP
Volume
21
Issue
3
Year of publication
2001
Pages
213 - 221
Database
ISI
SICI code
1386-6532(200106)21:3<213:DAPMOH>2.0.ZU;2-4
Abstract
Human cytomegalovirus (HCMV) infections are frequently observed as well in immunocompetent as in immunocompromised patients. Diagnostic techniques for HCMV detection have greatly improved during the recent years. Detection of HCMV by culture has been bettered by centrifugating samples in a shell via l and by using monoclonal antibody to the immediate early antigen. Detectio n of antigens in leucocytes was facilitated by using whole blood instead of leucocytes separated by dextran sedimentation. Detection of HCMV recently sharpened by using molecular biology methods mainly based on the detection of the genome. Under certain circumstances, and especially in pregnant wome n, diagnosis of HCMV infection is essentially based on the detection of IgG and IgM antibodies. However, as IgM antibody is not a marker of primary in fection, complementary tests are needed to help in the datation of the infe ction. Among them, the measurement of IgG avidity greatly improved the diag nosis of primary infections. In immunocompromised patients, very sensitive techniques are needed to diagnose HCMV infections. Detection of antigenemia and HCMV DNA are the methods of choice for an early detection of the infec tion. Diagnosis of HCMV-organ diseases largely depends on the infected orga n and the presence of HCMV in the organ is, sometimes, difficult to interpr et. Today, diagnosis of congenital infections is possible by detecting HCMV in the amniotic fluid. However, in order to reliably detect HCMV, amniocen tesis must be performed after 21 week's gestation and at least 6 weeks afte r seroconversion. As all HCMV infections do not induce disease, prognostic markers are needed, as well in immunocompromised patients as in fetuses. Ma ny studies were conducted in immunocompromised patients to find prognostic markers of HCMV infection in order to introduce preemptive therapy when nee ded. It seems that quantitative determination of HCMV DNA could be very use ful to predict HCMV disease. Qualitative determination of mRNA could also b e useful as a prognostic marker of HCMV disease. Determination of viral gen otypes is more controversial. As for the infected fetuses, little was publi shed about the prediction of sequelae. Some factors, such as viral load in amniotic fluid or in fetal blood or level of IgM antibody in fetal blood, m ay be predictive of sequelae, but these data require further studies. (C) 2 001 Elsevier Science B.V. All rights reserved.